UBI Pharma Achieves Another Milestone in the US Market: Its Anti-Fungal Injection Generic Product Approved by the US FDA 2023 年 3 月 15 日 Read More
UBI Pharma Expands Southeast Asian Market: Epilepsy Drug Levetiracetam Was Approved in Malaysia 2023 年 3 月 15 日 Read More
Bioequivalence Study is Completed for UBI Pharma’s New Formulation New Drug NDF01, and Will Proceed to NDA Filing Soon 2022 年 11 月 29 日 Read More
UBI Pharma passed the TTQS(Talent Quality-management System) assessment and received the bronze medal 2022 年 11 月 22 日 Read More
The Clinical Study Report of the Phase III Clinical Trial of UBI Pharma’s Recombinant Human Erythropoietin Biosimilar Drug UB-851 Has Been Completed 2022 年 1 月 20 日 Read More
The Production Line of UBI Pharma for Manufacturing Sterile Injectable Drugs Has Been Approved by the U.S. Food and Drug Administration 2019 年 8 月 15 日 Read More
